Identification of potential serum biomarkers for gastric cancer by a novel computational method, multiple normal tissues corrected differential analysis

Clinica Chimica Acta

Volumn 413, Issue 3-4, 2012, Pages 428-433

  Kim, Mirang ^a   Kim, Hyun Ja ^b   Choi, Bo Youl ^b   Kim, Jeong Hwan ^a   Song, Kyu Sang ^c   Noh, Seung Moo ^c   Kim, Jin Cheon ^d   Han, Dong Soo ^e   Kim, Seon Young ^a   Kim, Yong Sung ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Hanyang University College of Medicine   (South Korea)

^c Chungnam National University   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e Hanyang University Guri Hospital   (South Korea)

Author keywords

Gastric cancer; MMP 1; Prognostic biomarker

Indexed keywords

EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; STROMELYSIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DISEASE MARKER; ENZYME BLOOD LEVEL; FEMALE; GASTRECTOMY; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; MULTIPLE NORMAL TISSUES CORRECTED DIFFERENTIAL ANALYSIS; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; UPREGULATION;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COMPUTATIONAL BIOLOGY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84355161472     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.10.026     Document Type: Article

References (32)

1. Brenner H., Rothenbacher D., Arndt V. Epidemiology of stomach cancer. Methods Mol Biol 2009, 472:467-477.
2. Hamashima C., Shibuya D., Yamazaki H., et al. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol 2008, 38:259-267.
3. Ucar E., Semerci E., Ustun H., Yetim T., Huzmeli C., Gullu M. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. Adv Ther 2008, 25:1075-1084.
4. Louhimo J., Kokkola A., Alfthan H., Stenman U.H., Haglund C. Preoperative hCGbeta and CA 72-4 are prognostic factors in gastric cancer. Int J Cancer 2004, 111:929-933.
5. Mattar R., Alves de Andrade C.R., DiFavero G.M., Gama-Rodrigues J.J., Laudanna A.A. Preoperative serum levels of CA 72-4, CEA, CA 19-9, and alpha-fetoprotein in patients with gastric cancer. Rev Hosp ClÍn 2002, 57:89-92.
6. Lai I.R., Lee W.J., Huang M.T., Lin H.H. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence. Hepatogastroenterology 2002, 49:1157-1160.
7. Kochi M., Fujii M., Kanamori N., et al. Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer. Gastric Cancer 2000, 3:177-186.
8. Baek K.E., Yoon S.R., Kim J.T., et al. Upregulation and secretion of macrophage inhibitory cytokine-1 (MIC-1) in gastric cancers. Clin Chim Acta 2009, 401:128-133.
9. Park J.Y., Park K.H., Bang S., et al. CXCL5 overexpression is associated with late stage gastric cancer. J Cancer Res Clin Oncol 2007, 133:835-840.
10. Qian H.G., Shen J., Ma H., et al. Preliminary study on proteomics of gastric carcinoma and its clinical significance. World J Gastroenterol 2005, 11:6249-6253.
11. Tan S.H., Ida H., Lau Q.C., et al. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol Rep 2007, 18:1225-1230.
12. Ludwig J.A., Weinstein J.N. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005, 5:845-856.
13. Klee E.W. Data mining for biomarker development: a review of tissue specificity analysis. Clin Lab Med 2008, 28:127-143. [viii].
14. Klee E.W., Finlay J.A., McDonald C., et al. Bioinformatics methods for prioritizing serum biomarker candidates. Clin Chem 2006, 52:2162-2164.
15. da Costa L.F. Return of de-differentiation: why cancer is a developmental disease. Curr Opin Oncol 2001, 13:58-62.
16. Jin H., Lee H.C., Park S.S., Jeong Y.S., Kim S.Y. Serum cancer biomarker discovery through analysis of gene expression data sets across multiple tumor and normal tissues. J Biomed Inform 2011.
17. Safran M., Dalah I., Alexander J., et al. GeneCards version 3: the human gene integrator. Database (Oxford) 2010, 2010:baq020.
18. Otani Y., Okazaki I., Arai M., et al. Gene expression of interstitial collagenase (matrix metalloproteinase 1) in gastrointestinal tract cancers. J Gastroenterol 1994, 29:391-397.
19. Sakurai Y., Otani Y., Kameyama K., et al. Expression of interstitial collagenase (matrix metalloproteinase-1) in gastric cancers. Jpn J Cancer Res 1997, 88:401-406.
20. Inoue T., Yashiro M., Nishimura S., et al. Matrix metalloproteinase-1 expression is a prognostic factor for patients with advanced gastric cancer. Int J Mol Med 1999, 4:73-77.
21. Mizutani K., Kofuji K., Shirouzu K. The significance of MMP-1 and MMP-2 in peritoneal disseminated metastasis of gastric cancer. Surg Today 2000, 30:614-621.
22. Fujimoto D., Hirono Y., Goi T., Katayama K., Yamaguchi A. Prognostic value of protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1) in gastric cancer. Anticancer Res 2008, 28:847-854.
23. Bao W., Fu H.J., Jia L.T., et al. HER2-mediated upregulation of MMP-1 is involved in gastric cancer cell invasion. Arch Biochem Biophys 2010, 499:49-55.
24. Yeh Y.C., Sheu B.S., Cheng H.C., Wang Y.L., Yang H.B., Wu J.J. Elevated serum matrix metalloproteinase-3 and -7 in H. pylori-related gastric cancer can be biomarkers correlating with a poor survival. Dig Dis Sci 2010, 55:1649-1657.
25. Oue N., Sentani K., Noguchi T., et al. Serum olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients. Int J Cancer 2009, 125:2383-2392.
26. Macri A., Versaci A., Loddo S., et al. Serum levels of interleukin 1beta, interleukin 8 and tumour necrosis factor alpha as markers of gastric cancer. Biomarkers 2006, 11:184-193.
27. Konno H., Ohta M., Baba M., Suzuki S., Nakamura S. The role of circulating IL-8 and VEGF protein in the progression of gastric cancer. Cancer Sci 2003, 94:735-740.
28. Choi E.H., Kim J.T., Kim J.H., et al. Upregulation of the cysteine protease inhibitor, cystatin SN, contributes to cell proliferation and cathepsin inhibition in gastric cancer. Clin Chim Acta 2009, 406:45-51.
29. Choi S.R., Jang J.S., Lee J.H., et al. Role of serum tumor markers in monitoring for recurrence of gastric cancer following radical gastrectomy. Dig Dis Sci 2006, 51:2081-2086.
30. Ohtsuka T., Sato S., Kitajima Y., Tanaka M., Nakafusa Y., Miyazaki K. False-positive findings for tumor markers after curative gastrectomy for gastric cancer. Dig Dis Sci 2008, 53:73-79.
31. Ohtsuka T., Nakafusa Y., Sato S., Kitajima Y., Tanaka M., Miyazaki K. Different roles of tumor marker monitoring after curative resections of gastric and colorectal cancers. Dig Dis Sci 2008, 53:1537-1543.
32. Shin G., Kang T.W., Yang S., Baek S.J., Jeong Y.S., Kim S.Y. GENT: gene expression database of normal and tumor tissues. Cancer Inform 2011, 10:149-157.